Related Experiment Videos
Long-acting beta-agonists role in asthma management.
1Division of Pulmonary Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
The Journal of Family Practice
|May 24, 2006
Summary
Long-acting beta-agonists (LABAs) aid asthma control but carry risks. Current guidelines restrict LABA use to patients not managed by inhaled corticosteroids alone, emphasizing safety and efficacy.
Area of Science:
- Pulmonology
- Pharmacology
- Asthma Management
Background:
- Long-acting beta-agonists (LABAs) have been integral to asthma management for a decade.
- LABAs improve lung function and reduce symptoms when combined with anti-inflammatory agents.
Purpose of the Study:
- To review the role of LABAs in asthma therapy.
- To address safety concerns and restricted indications for specific LABA products.
Main Methods:
- Review of clinical studies and guidelines.
- Analysis of safety data associated with LABA use.
Main Results:
- LABAs are beneficial with anti-inflammatory agents but linked to negative outcomes.
- Salmeterol is associated with increased asthma-related deaths; formoterol with exacerbations.
- Restricted indications and medication guides are now required for certain LABA products.
Conclusions:
- LABAs remain important in asthma therapy but require careful patient selection.
- Use is restricted to patients inadequately controlled by inhaled corticosteroids or with severe disease.
- Further data from SMART analyses and NAEPP guidelines will clarify LABA's role.